Sevelamer Suspension in Children with End-Stage Renal Disease
Download in electronic PDF format for $65
Abstract: Control of hyperphosphatemia is a major clinical challenge in children with end-stage renal disease. The best treatment option is a calcium-based phosphate binder, but there is evidence that this treatment protocol causes long-term complications, including vascular calcifications. Sevelamer hydrochloride has been shown to be effective in reducing serum phosphorus levels and the calcium-phosphorus ion product in children on maintenance dialysis and may be key in preventing soft-tissue and vascular calcifications in such patients. Until the U.S. Food and Drug Administration approves the use of sevelamer hydrochloride in children undergoing dialysis, and a liquid dosage form becomes available, compounding pharmacists will need to prepare this unique compound for these patients.
Related Keywords:
CHILDREN, INFANTS, CHRONIC RENAL FAILURE, KIDNEY FAILURE, END-STAGE RENAL DISEASE, ESRD, HYPERPHOSPHATEMIA, FIXED OIL, RENAGEL, DIALYSIS, PHOSPHORUS, PHOSPHATE BINDERS, SEVELAMER HYDROCHLORIDE, ORAL SUSPENSION, LIQUID PREPARATIONS, DOSAGE FORMS, FORMULATI
Related Categories:
FORMULATIONS, NUTRITION AND NUTRICEUTICALS, PEDIATRICS, STABILITIES, COMPATIBILITIES, UROLOGY/URINARY TRACT
Printer-Friendly Version
| Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Sevelamer Suspension in Children with End-Stage Renal Disease
McElhiney Linda F
|
Jan/Feb 2007
Pg. 20-24
|
Compounded Oral Ketamine for Severe Depression, Anxiety, and Pain in a Hospice Patient with End-stage Chronic Obstructive Pulmonary Disease, Cardiopulmonary Failure, and Severe Renal Insufficiency: A Case Report
McNulty Jack P, Hahn Kristian
|
Sep/Oct 2012
Pg. 364-368
|
Conservative Management of Chronic Kidney Disease in Cats: Recommendations for Veterinarians and Compounding Pharmacists
Meadows Richard L, Muller George
|
Sep/Oct 2010
Pg. 382-394
|
Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4
Polonini Hudson, da Silva Sharlene Loures, Brandão Marcos Antônio Fernandes, Bauters Tiene, De Moerloose Barbara, Ferreira Anderson de Oliveira
|
Nov/Dec 2018
Pg. 516-526
|
Stability of Oral Liquid Dosage Forms of Ethacrynic Acid
Gupta Vishnu D, Ling Jie
|
May/Jun 2001
Pg. 232-233
|
Basics of Compounding for Raynaud's Disease
Glasnapp Andrew
|
Jul/Aug 2003
Pg. 288-291
|
Treating Canine Hepatic Disease
Davidson Gigi S
|
May/Jun 2003
Pg. 188-191
|
Pediatric Compounding: Coloring Outside the Lines
Preckshot John
|
Jan/Feb 2001
Pg. 6-8
|
Extended Stability of Morphine and Sildenafil for Oral Use in Infants and Young Children
Nahata Milap C
|
May/Jun 2016
Pg. 247-249
|
The Treatment of Canine Atopic Disease
Davidson Gigi S
|
May/Jun 2002
Pg. 210-215
|
